Abstract:Inflammation is central to pathogenic processes in diabetes mellitus and the metabolic syndrome and particularly implicates innate immunity in the development of complications. Inflammation is a primary event in Type 1 diabetes where infectious (viral) and/or autoimmune processes initiate disease; in contrast, chronic inflammation is typical in Type 2 diabetes and is considered a sequel to increasing insulin resistance and disturbed glucose metabolism. Diabetic retinopathy (DR) is perceived as a vascular and neurodegenerative disease which occurs after some years of poorly controlled diabetes. However, many of the clinical features of DR are late events and reflect the nature of the retinal architecture and its cellular composition. Retinal microvascular disease is, in fact, an early event pathogenetically, induced by low grade, persistent leukocyte activation which causes repeated episodes of capillary occlusion and, progressive, attritional retinal ischemia. The later, overt clinical signs of DR are a consequence of the retinal ischemia. Metabolic dysregulation involving both lipid and glucose metabolism may lead to leukocyte activation. On a molecular level, we have shown that macrophage-restricted protein tyrosine phosphatase 1B (PTP1B) is a key regulator of inflammation in the metabolic syndrome involving insulin resistance and it is possible that PTP1B dysregulation may underlie retinal microvascular disease. We have also shown that adherent CCR5<sup>+</sup>CD11b<sup>+</sup> monocyte macrophages appear to be selectively involved in retinal microvascular occlusion. In this review, we discuss the relationship between early leukocyte activation and the later features of DR, common pathogenetic processes between diabetic microvascular disease and other vascular retinopathies, the mechanisms whereby leukocyte activation is induced in hyperglycemia and dyslipidemia, the signaling mechanisms involved in diabetic microvascular disease, and possible interventions which may prevent these retinopathies. We also address a possible role for adaptive immunity in DR. Although significant improvements in treatment of DR have been made with intravitreal anti-VEGF therapy, a sizeable proportion of patients, particularly with sight-threatening macular edema, fail to respond. Alternative therapies targeting inflammatory processes may offer an advantage.

The Role of Immune Cells and Signaling Pathways in Diabetic Eye Disease: A Comprehensive Review

Diabetic Keratopathy: Redox Signaling Pathways and Therapeutic Prospects

The role of inflammation in diabetic eye disease

Diabetic Retinopathy: Vascular and Inflammatory Disease

The innate immune system in diabetic retinopathy

Current understanding of the molecular and cellular pathology of diabetic retinopathy

The Role of Inflammation in Diabetic Retinopathy

Molecular Mechanisms of Diabetic Retinopathy, General Preventive Strategies, and Novel Therapeutic Targets

The Adaptive Immune System in the Retina of Diabetes

Immune-Mediated Ocular Surface Disease in Diabetes Mellitus—Clinical Perspectives and Treatment: A Narrative Review

The role of inflammation in immune system of diabetic retinopathy: Molecular mechanisms, pathogenetic role and therapeutic implications

NOD-like Receptors in the Eye: Uncovering Its Role in Diabetic Retinopathy

Diabetes mellitus associated neurovascular lesions in the retina and brain: A review

Diabetic Macular Edema: Current Understanding, Molecular Mechanisms and Therapeutic Implications

Diabetic Retinopathy: From Animal Models to Cellular Signaling

Pathological ocular angiogenesis in diabetes: A perspective of emerging paradigms and current evidence

Advancement in Understanding Diabetic Retinopathy: A Comprehensive Review

Diabetic retinopathy and endothelin system: microangiopathy versus endothelial dysfunction

Diabetic retinopathy: current understanding, mechanisms, and treatment strategies

Roles and Perspectives of Inflammatory Factors in Diabetic Macular Edema

Emerging role of extracellular vesicles in diabetic retinopathy